Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD® trial
Claudia Valenzuela,1 Toby M Maher,2 Francesco Bonella,3 Alberto Pesci,4 Stephane Jouneau,5 Nina M Patel,6 Evans R. Fernández Pérez,7 Rainer-Georg Goeldner,8 Susanne Stowasser,9 Rozsa Schlenker-Herceg,10 Vincent Cottin11 on behalf of the INBUILD trial investigators
1Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Madrid, Spain; 2National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA; 3Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, Duisburg-Essen University, Essen, Germany; 4Milano-Bicocca University-ASST, Monza, Italy; 5Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; 6Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, NY, USA; 7National Jewish Health, Denver, CO, USA; 8Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 9Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 10Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 11Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France
Introduction
- In patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, decline in forced vital capacity (FVC) is predictive of mortality.1-4
- In the INBUILD trial in subjects with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed the rate of decline in FVC (mL/year) over 52 weeks by 57% versus placebo (difference 107.0 mL/year [95% CI: 65.4, 148.5]).5
